AtriCure Announces Commencement of Public Offering of Common Stock
AtriCure (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems for the treatment of atrial fibrillation, or AF, and systems for the exclusion of the left atrial appendage, today announced that it intends to offer shares of its common stock in a public offering. Piper Jaffray & Co. is acting as the sole manager for the offering.
AtriCure plans to use the net proceeds from the offering for general corporate purposes and working capital.
This offering will be made pursuant to a prospectus supplement to AtriCure's prospectus, dated July 20, 2011, filed as part of AtriCure's effective $50 million shelf registration statement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
Copies of the preliminary prospectus supplement and accompanying prospectus relating to these securities may be obtained by contacting Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402 or by telephone at 800-747-3924 or by email at firstname.lastname@example.org.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.